171 related articles for article (PubMed ID: 21336242)
1. Immunosuppressive therapy after kidney transplantation: current and new strategies.
Metalidis C; Kuypers D
Minerva Urol Nefrol; 2011 Mar; 63(1):1-19. PubMed ID: 21336242
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression after kidney transplantation.
Kihm LP; Zeier M; Morath C
Minerva Urol Nefrol; 2011 Mar; 63(1):45-57. PubMed ID: 21336245
[TBL] [Abstract][Full Text] [Related]
3. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
Boswell A; Evans L; Rigg K; Shehata M
Transplant Proc; 2005 Mar; 37(2):884-5. PubMed ID: 15848564
[TBL] [Abstract][Full Text] [Related]
8. [Immunosuppression for kidney transplant recipients: current strategies].
Alberú J; Urrea EM
Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
Kamar N; Del Bello A; Belliere J; Rostaing L
Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
11. Current concepts and perspectives of immunosuppression in organ transplantation.
Scherer MN; Banas B; Mantouvalou K; Schnitzbauer A; Obed A; Krämer BK; Schlitt HJ
Langenbecks Arch Surg; 2007 Sep; 392(5):511-23. PubMed ID: 17450373
[TBL] [Abstract][Full Text] [Related]
12. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
Staatz CE; Tett SE
Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
[TBL] [Abstract][Full Text] [Related]
15. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin-inhibitor minimization protocols in heart transplantation.
Zuckermann AO; Aliabadi AZ
Transpl Int; 2009 Jan; 22(1):78-89. PubMed ID: 18954366
[TBL] [Abstract][Full Text] [Related]
17. [Immunosuppressive treatments: mechanisms of action and clinical use].
Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin inhibitor-free protocols: risks and benefits.
Barbari AG; Stephan AG; Masri MA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
[TBL] [Abstract][Full Text] [Related]
19. There is a choice for immunosuppressive drug nephrotoxicity: Is it time to change?
Stallone G; Infante B; Gesualdo L
J Nephrol; 2009; 22(3):326-32. PubMed ID: 19557709
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor-free immunosuppression in renal transplantation.
Parada B; Mota A; Nunes P; Macário F; Pratas J; Bastos C; Figueiredo A
Transplant Proc; 2005; 37(6):2759-61. PubMed ID: 16182803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
